Instil Bio
78 hedge funds and large institutions have $1.27B invested in Instil Bio in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 10 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
1% more funds holding
Funds holding: 77 → 78 (+1)
0.07% more ownership
Funds ownership: 4.5% → 4.57% (+0.07%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
36% less capital invested
Capital invested by funds: $1.99B → $1.27B (-$717M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.9M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.41M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.58M |
| 4 |
JP Morgan Chase
New York
|
+$2.29M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$21M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.98M |
| 3 |
CI
CPMG Inc
Dallas,
Texas
|
-$3.04M |
| 4 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$974K |
| 5 |
PM
Parametrica Management
Wanchai,
Hong Kong
|
-$867K |
TIL Hedge Fund Activity: Q1 2022 in Review
78 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q1 2022, worth a combined $1.27B — down 36% from $1.99B a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TIL positions and 10 closed out — a net gain of 1 holder — while 24 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $37.9M. The largest seller was Wellington Management Group, cutting an estimated $21M.
- 78 institutional investors held Instil Bio (TIL) as of Q1 2022, up from 77 in Q4 2021.
- Funds reported $1.27B of Instil Bio stock for Q1 2022, down 36% quarter-over-quarter.
- 11 funds opened new Instil Bio positions in Q1 2022 and 10 closed out, a net change of +1 holder.
- The largest Instil Bio buyer in Q1 2022 was Fidelity Investments, an estimated $37.9M added.
- The largest Instil Bio seller in Q1 2022 was Wellington Management Group, an estimated $21M sold.
Based on aggregated 13F filings for Q1 2022.